Relapsed large B-cell lymphoma remains difficult to treat after multiple lines, and antibody-drug conjugates offer a way to concentrate cytotoxic payloads on B cells. Zynlonta (loncastuximab tesirine) targets CD19.
Once internalized, it releases a pyrrolobenzodiazepine dimer that cross-links DNA and kills the lymphoma cell. The CD19-directed antibody-drug conjugate is infused for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Zynlonta’s accelerated approval remains ongoing, keeping its confirmatory trial obligation an open regulatory item. It sits in a CD19-crowded space alongside CAR-T and bispecific antibodies, making sequencing and retreatment after CD19-directed therapy the central competitive question.
